Chronic lymphocytic leukaemia: open trials in Greece

6 open trials have a site in Greece. Registry data; only the trial team decides who can take part.

NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
GENERAL HOSPITAL OF ALEXANDROUPOLI (Site 2310), Alexandroupoli · Evangelismos General Hospital of Athens (Site 2302), Athens · General Hospital of Athens "Laiko" (Site 2309), Athens · General Hospital of Athens "Laiko" (Site 2308), Athens
Registry updated 2026-11-06
NCT06588478
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Trial Treatment · Phase 2 · Loxo Oncology, Inc.
Evangelismos General Hospital of Athens, Athens · Attikon General University Hospital, Chaïdári · G. Papanikolaou General Hospital, Thessaloniki · General Hospital of Athens "Laiko", Αthens
Registry updated 2026-11-04
NCT06788509
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Trial Treatment · Phase 1 · Janssen Research & Development, LLC
General Hospital of Athens - Alexandra, Athens
Registry updated 2026-11-04
NCT06136559
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
University General Hospital of Alexandroupoli, Alexandroupoli · Laiko General Hospital of Athens, Athens · Evangelismos S A, Athens · University General Hospital of Ioannina, Ioannina
Registry updated 2026-10-13
NCT06980116
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Trial Treatment · Phase 1 · Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Laiko General Hospital of Athens, Athens · General University Hospital Of Patras, Patras · Geniko Nosokomeio Thessalonikis George Papanikolaou, Thessaloniki
Registry updated 2026-08-13
NCT06428019
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Trial Treatment · Phase 3 · AbbVie
University General Hospital of Alexandroupoli, Alexandroupoli · Evangelismos S A, Athens · University General Hospital Attikon, Athens · Laiko General Hospital of Athens, Athens · Olympion Therapeftirio General Clinic Of Patras S.A., Patra
Registry updated 2026-04-09

All Chronic lymphocytic leukaemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error

Chronic lymphocytic leukaemia: open trials in Greece

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)